Effect of Estrogen Therapy on Objective Sleep Quality in Postmenopausal Women

NCT ID: NCT01501422

Last Updated: 2012-12-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-07-31

Study Completion Date

2012-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Sex hormone including estrogen have synergistic effect to serotonin activity and decrease activity of monoamine oxidase activity so the norepinephrine is not be metabolized, these substance are important to regulate hemostasis and circadian process of sleep
2. Estrogen also regulate gamma-aminobutyric acid (GABA) secretion

* GABA substance is in order to initiate sleep and continue sleep
3. According to epidemiologic data, problem of sleep was increasing in postmenopause group compare to premenopause group (aged-match)
4. This research perform to find out the actual effect of estrogen in improving sleep quality.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. 40-60 year-old postmenopausal women with insomnia and mild-moderate vasomotor symptom were screened and included in project
2. Block of four randomization was use to categorize participants into 2 groups

* Study group (estrogen patch)
* Control group (placebo patch)
3. Sleep quality was measured before intervention by subjective and objective sleep quality

* Subjective sleep quality (self sleep questionnaire)
* Objective sleep quality (wrist actigraphy and sleep diary):

wrist actigraph sleep test at home for 1 week
4. Intervention phase : continuous use of weekly patch for 8 weeks

* Estrogen patch in study group
* Placebo patch in control group
5. Follow up phase

* At 4 weeks of use, investigator will telephone call for follow up the participant's compliance and the side effects during patch use.
* After completed use of 7th patch, sleep quality was measured again, self sleep quality questionnaire and 1 week-wrist actigraphy and sleep diary test
6. Then the data will be analysed and open label, in nonhysterectomized postmenopausal women in study group will take the medroxyprogesterone acetate for washing out the endometrium for 2 weeks
7. The participants will be counseled, further investigate and proper treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Insomniac Postmenopausal Women

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

postmenopause sleep quality estrogen objective sleep quality actigraph

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Estrogen

Use estrogen patch for 8 weeks

Group Type EXPERIMENTAL

Estrogen patch

Intervention Type DRUG

50 microgram estrogen patch weekly

Placebo

Use placebo patch for 8 weeks

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Placebo patch for 8 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Estrogen patch

50 microgram estrogen patch weekly

Intervention Type DRUG

Placebo

Placebo patch for 8 weeks

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Postmenopausal women 40-60 years old
* Mild to moderate vasomotor symptom
* Insomnia
* fluent read and write in Thai language
* Inform consent

Exclusion Criteria

* Acute liver and gall bladder disease
* undiagnosed abnormal bleeding per vagina
* History of BIRADs 3 from mammogram
* History or current venous thrombosis, embolism
* diagnosis of sleep disorder
* use of hypnotic drug or antihistamine in the past month
* Diagnosis of psychiatric disorder such as depressive disorder, schizophrenia, anxiety disorder
* No past history of malignancy
* No history of chronic renal disease, alzheimer's disease, uncontrolled hypertension, uncontrolled diabetes mellitus
* history of estrogen use in past 6 months
* drug abuse, Alcohol
Minimum Eligible Age

40 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chulalongkorn University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pimpika Tansupswatdikul, MD.

Principle investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pimpika Tansupswatdikul, MD.

Role: PRINCIPAL_INVESTIGATOR

Chulalongkorn University

Sukanya Chaikiitisilpa, MD.

Role: STUDY_CHAIR

Chulalongkorn University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Menopause Clinic, Menopause research unit, King Chulalongkorn Memorial Hospital

Pathumwan, Bangkok, Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

References

Explore related publications, articles, or registry entries linked to this study.

Kalleinen N, Polo O, Himanen SL, Joutsen A, Polo-Kantola P. The effect of estrogen plus progestin treatment on sleep: a randomized, placebo-controlled, double-blind trial in premenopausal and late postmenopausal women. Climacteric. 2008 Jun;11(3):233-43. doi: 10.1080/13697130802112033.

Reference Type BACKGROUND
PMID: 18568788 (View on PubMed)

Huang KE, Baber R; Asia Pacific Tibolone Consensus Group. Updated clinical recommendations for the use of tibolone in Asian women. Climacteric. 2010 Aug;13(4):317-27. doi: 10.3109/13697131003681458.

Reference Type BACKGROUND
PMID: 20443720 (View on PubMed)

Halbreich U, Kahn LS. Role of estrogen in the aetiology and treatment of mood disorders. CNS Drugs. 2001;15(10):797-817. doi: 10.2165/00023210-200115100-00005.

Reference Type BACKGROUND
PMID: 11602005 (View on PubMed)

Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc. 2002 Nov;77(11):1207-18. doi: 10.4065/77.11.1207.

Reference Type BACKGROUND
PMID: 12440557 (View on PubMed)

Sarti CD, Chiantera A, Graziottin A, Ognisanti F, Sidoli C, Mincigrucci M, Parazzini F; Gruppo di Studio IperAOGOI. Hormone therapy and sleep quality in women around menopause. Menopause. 2005 Sep-Oct;12(5):545-51. doi: 10.1097/01.gme.0000172270.70690.5e. Epub 2005 Sep 1.

Reference Type BACKGROUND
PMID: 16145308 (View on PubMed)

Wiklund I, Berg G, Hammar M, Karlberg J, Lindgren R, Sandin K. Long-term effect of transdermal hormonal therapy on aspects of quality of life in postmenopausal women. Maturitas. 1992 Mar;14(3):225-36. doi: 10.1016/0378-5122(92)90117-m.

Reference Type BACKGROUND
PMID: 1508062 (View on PubMed)

Polo-Kantola P, Erkkola R, Helenius H, Irjala K, Polo O. When does estrogen replacement therapy improve sleep quality? Am J Obstet Gynecol. 1998 May;178(5):1002-9. doi: 10.1016/s0002-9378(98)70539-3.

Reference Type BACKGROUND
PMID: 9609575 (View on PubMed)

Saletu B. Sleep, vigilance and cognition in postmenopausal women: placebo-controlled studies with 2 mg estradiol valerate, with and without 3 mg dienogest. Climacteric. 2003 Aug;6 Suppl 2:37-45.

Reference Type BACKGROUND
PMID: 14669843 (View on PubMed)

Ensrud KE, Stone KL, Blackwell TL, Sawaya GF, Tagliaferri M, Diem SJ, Grady D. Frequency and severity of hot flashes and sleep disturbance in postmenopausal women with hot flashes. Menopause. 2009 Mar-Apr;16(2):286-92. doi: 10.1097/gme.0b013e31818c0485.

Reference Type BACKGROUND
PMID: 19002015 (View on PubMed)

Tranah GJ, Parimi N, Blackwell T, Ancoli-Israel S, Ensrud KE, Cauley JA, Redline S, Lane N, Paudel ML, Hillier TA, Yaffe K, Cummings SR, Stone KL. Postmenopausal hormones and sleep quality in the elderly: a population based study. BMC Womens Health. 2010 May 4;10:15. doi: 10.1186/1472-6874-10-15.

Reference Type BACKGROUND
PMID: 20441593 (View on PubMed)

Tansupswatdikul P, Chaikittisilpa S, Jaimchariyatam N, Panyakhamlerd K, Jaisamrarn U, Taechakraichana N. Effects of estrogen therapy on postmenopausal sleep quality regardless of vasomotor symptoms: a randomized trial. Climacteric. 2015 Apr;18(2):198-204. doi: 10.3109/13697137.2014.964670. Epub 2014 Nov 27.

Reference Type DERIVED
PMID: 25242569 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MRU CU-1/2011

Identifier Type: -

Identifier Source: org_study_id